Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Queensland Health
Express Scripts
Dow
Citi
Cipla
QuintilesIMS
Argus Health
Novartis
Cerilliant

Generated: February 20, 2018

DrugPatentWatch Database Preview

RAU-SED Drug Profile

« Back to Dashboard

Which patents cover Rau-sed, and when can generic versions of Rau-sed launch?

Rau-sed is a drug marketed by Bristol Myers Squibb and is included in one NDA.

The generic ingredient in RAU-SED is reserpine. There are nineteen drug master file entries for this compound. Additional details are available on the reserpine profile page.
Drug patent expirations by year for RAU-SED
Medical Subject Heading (MeSH) Categories for RAU-SED

US Patents and Regulatory Information for RAU-SED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb RAU-SED reserpine TABLET;ORAL 009357-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb RAU-SED reserpine TABLET;ORAL 009357-008 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb RAU-SED reserpine TABLET;ORAL 009357-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Bristol Myers Squibb RAU-SED reserpine TABLET;ORAL 009357-006 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Fuji
Chinese Patent Office
AstraZeneca
UBS
Colorcon
Queensland Health
Citi
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot